Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trialThomas Powles, Felipe Reyes, Blanca Homet Moreno et al.|The Lancet Oncology|2021Cited by 645
Circulating Tumor Cells as Potential Biomarkers in Bladder CancerAjjai Alva, Pamela L. Paris, Terence W. Friedlander et al.|The Journal of Urology|2015Cited by 88
Primary Urethral Clear-Cell AdenocarcinomaRohit Mehra, Arul M. Chinnaiyan, Pankaj Vats et al.|American Journal Of Pathology|2014Cited by 62
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Keith T. Flaherty, Alain C. Mita et al.|JCO Precision Oncology|2024Cited by 16
Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.Minas P. Economides, Scot A. Niglio, Matthew I. Milowsky et al.|Journal of Clinical Oncology|2023Cited by 8